Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PORT-5
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Portage Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to speci...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 03, 2022
Lead Product(s) : PORT-5
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Portage Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STI-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Portage Biotech
Deal Size : $0.9 million
Deal Type : Financing
Portage Makes Additional Investment in Stimunity S.A.S
Details : Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : STI-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Portage Biotech
Deal Size : $0.9 million
Deal Type : Financing
Reset All
